Holen Sie sich die Stockscreener-App
1.97
81.42%
-8.63
Handel nachbörslich:
2.08
0.11
+5.58%
Schlusskurs vom Vortag:
$10.60
Offen:
$1.88
24-Stunden-Volumen:
44.42M
Relative Volume:
25.64
Marktkapitalisierung:
$318.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-1.1465
EPS:
-1.7182
Netto-Cashflow:
$-198.33M
1W Leistung:
-82.63%
1M Leistung:
-79.90%
6M Leistung:
-79.90%
1J Leistung:
-88.34%
1-Tages-Spanne:
$1.83
$2.25
1-Wochen-Bereich:
$1.83
$11.57
52-Wochen-Spanne:
$1.83
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
490 ARSENAL WAY, SUITE 200, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.97 | 318.28M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.76 | 104.50B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.19 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.16 | 37.08B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.62 | 30.13B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.30 | 27.64B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
New Year’s Hangover: Neumora’s Phase III Failure In Depression Surprises - News & Insights
Results are in for a new depression drug trial, and they're cratering this stock - Yahoo Finance
Mass. biotech stock plunges after depression drug fails late-stage trial - The Business Journals
Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial - Yahoo Finance
Neumora shares sink following Phase III flop in MDD - Yahoo Finance
H.C. Wainwright still sees opportunity for Neumora despite trial miss - TipRanks
RBC Capital cuts Neumora Therapeutics stock rating to Sector Perform By Investing.com - Investing.com UK
Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to "Sector Perform" at Royal Bank of Canada - MarketBeat
Neumora Therapeutics and Other Stocks Suffer Major Losses as Market Faces Declines - HPBL
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Neumora plummets on depression drug data - BioPharma Dive
Neumora Therapeutics shares plummet as Phase 3 depression drug trial disappoints - Proactive Investors UK
Neumora Stock Dives After Study Failure - The Wall Street Journal
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops - MSN
Neumora Therapeutics Shares Plummet After Depression Drug Trial FailureNews and Statistics - IndexBox, Inc.
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals - Investopedia
Market movers: Unity Software, Bit Digital, Neumora Therapeutics, HIVE... - Proactive Investors USA
Stock in Biotech Neumora Plunges 80% as Depression Drug Fails - MSN
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals - MarketWatch
Needham & Company LLC Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Stock market today: Neumora Therapeutics down by 81.14% while Rain Oncology surged by 676.86% in early trading - Business Upturn
Neumora Therapeutics stock hits 52-week low at $1.89 - Investing.com
Neumora trial failure a ‘big blow’ to bull case, says Stifel - TipRanks
Neumora’s Novel Depression Drug Strikes Out in First Pivotal Trial - BioSpace
Neumora laid low by depression trial failure - pharmaphorum
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials - Yahoo Finance
Neumora (NMRA) Plunges After Depression Drug Fails in Final-Stage Study - Bloomberg
Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints -- Update - MarketWatch
Neumora's depression drug misses main goal in study - Investing.com
Neumora stock drops on depression trial failure (NMRA:NASDAQ) - Seeking Alpha
Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression - TipRanks
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder - The Manila Times
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Shares Down 4.3%What's Next? - MarketBeat
Head to Head Comparison: LadRx (OTCMKTS:CYTR) versus Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Franklin Resources Inc. Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Barclays PLC Buys 100,678 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Barclays PLC - Defense World
Neumora Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Increases Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Shares Up 7.2%Here's Why - MarketBeat
This Is What Whales Are Betting On Neumora Therapeutics - Benzinga
Neumora: KOASTAL-1 Readout For MDD Treatment Is First Study On Deck (NMRA) - Seeking Alpha
Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3%Time to Sell? - MarketBeat
Neumora Therapeutics Target of Unusually High Options Trading (NASDAQ:NMRA) - Defense World
Neumora Therapeutics Sees Unusually High Options Volume (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by State Street Corp - MarketBeat
State Street Corp Has $23.66 Million Stock Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Commit To Buy Neumora Therapeutics At $5, Earn 105.2% Annualized Using Options - Nasdaq
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):